Eli Lilly and : Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack -April 06, 2024 at 09:54 am EDT

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® on risk of heart


failure hospitalization and death in adults following a...

Related Keywords

,Jeff Emmick ,Mohamed Eid ,Eli Lilly ,Duke Clinical Research Institute ,Product Development ,Boehringer Ingelheim Pharmaceuticals Inc ,Boehringer Ingelheim ,American College Of Cardiology ,Clinical Development Medical Affairs ,Lilly Alliance ,American College ,New England Journal ,Clinical Development ,Medical Affairs ,Cardio Renal Metabolic Medicine ,Boehringer Ingelheim Pharmaceuticals ,Myocardial Infarction ,Markets ,